Tompkins Financial Corp Sells 1,871 Shares of Johnson & Johnson $JNJ

Tompkins Financial Corp trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,984 shares of the company’s stock after selling 1,871 shares during the quarter. Tompkins Financial Corp’s holdings in Johnson & Johnson were worth $5,344,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Elios Financial Group Inc. grew its holdings in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC lifted its position in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC grew its stake in shares of Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares during the period. Sovereign Financial Group Inc. increased its holdings in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc raised its stake in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after acquiring an additional 69 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JNJ. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Finally, Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $177.87.

Johnson & Johnson Price Performance

JNJ stock opened at $176.98 on Thursday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The stock has a market cap of $426.23 billion, a PE ratio of 18.93, a P/E/G ratio of 2.25 and a beta of 0.40. The company has a 50-day moving average price of $172.09 and a 200 day moving average price of $161.57.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.